Role of immune cells in the pavlovian conditioning of specific resistance to cancer

References

• Berd D. Immunotherapy of melanoma with autologous tumor vaccine preceded by low dose cyclophosphamide. In. Human tumor antigens and specific tumor therapy. Alan R. Liss, Inc. 1989; 297–306
   Google Scholar
• Berd D., Maguire H. C., Jr., Mastrangelo M. J. Induction of cell-mediated immunity to autologous melanoma cells and regression of metastases after treatment with a melanoma cell vaccine preceded by cyclophosphamide. Cancer Research 1986; 46: 2572–2577
   PubMed Web of Science ®Google Scholar
• Berendt M. J., North R. J. T-cell-mediated suppression of anti-tumor immunity. An explanation for progressive growth of an immunogeneic tumor. Journal of Experimental Medicine 1980; 151: 69–80
   PubMed Web of Science ®Google Scholar
• Bystryn J-C., Dugan M., Oratz R., Speyer J., Harris M. N., Roses D. F. Vaccine immunotherapy of human malignant melanoma: relationship between method of immunization, immunogenicity, and tumor progression. Human tumor antigens and specific tumor therapy, R. S. Metzgar, M. Mitchell. Alan R. Liss, Inc, New York 1989; 307–315
   Google Scholar
• Cheever M. A., Greenberg P. D., Fefer A. Potential for specific cancer therapy with immune T-lymphocytes. Journal of Biological Response Modifiers 1984; 3: 113–127
   PubMedGoogle Scholar
• Cheever M. A., Thompson J. A., Kern D. E., Greenberg P. D. Interleukin-2 (IL-2) administered in vivo: influence of IL-2 route and timing on T-cell growth. The Journal of Immunology 1985; 134: 3895–3900
   PubMed Web of Science ®Google Scholar
• Cunningham T. J., Olson K. B., Laffin R., Horton J., Sullivan J. Treatment of advanced cancer with active immunization. Cancer 1969; 24: 932–937
   PubMed Web of Science ®Google Scholar
• Dye E. S., North R. J. T-cell-mediated immunosuppression as an obstacle to adoptive immunotherapy of the P815 mastocytoma and its metastasis. Journal of Experimental Medicine 1981; 154: 1033–1042
   PubMed Web of Science ®Google Scholar
• Fareed G. C., Mendiaz E., Sen A., Juillard G. J. F., Weisenburger T. H., Totanes T. Novel antigenic markers of human tumor regression. Journal of Biological Response Modifiers 1988; 7: 11–23
   PubMedGoogle Scholar
• Ghanta V. K., Hiramoto R. N., Solvason H. B., Spector N. H. Influence of conditioned natural immunity on tumor growth. Annals of the New York Academy of Science 1987; 496: 637–641
   PubMed Web of Science ®Google Scholar
• Ghanta V. K., Hiramoto N. S., Solvason H. B., Soong S-J., Hiramoto R. N. Conditioning: a new approach to immunotherapy. Cancer Research 1990; 50: 4295–4299
   PubMed Web of Science ®Google Scholar
• Goodnight J. E., Morton D. C. Immunotherapy for malignant disease. Annual Reviews of Medicine 1978; 29: 231–283
   PubMed Web of Science ®Google Scholar
• Gorczynski R. M., Kennedy M., Ciampi A. Cimetidine reverses tumor growth enhancement of plasmacytoma tumors in mice demonstrating conditioned immunosuppression. The Journal of Immunology 1985; 134: 4261–4266
   PubMed Web of Science ®Google Scholar
• Greenberg P. D., Cheever M. A. Effector mechanisms operative in adoptive therapy of tumor-bearing animals: implication for the use of interleukin-2. Journal of Biological Response Modifiers 1984; 3: 455–461
   PubMedGoogle Scholar
• Greenberg P. D., Cheever M. A. Treatment of disseminated leukemia with cyclophosphamide and immune cells: tumor immunity reflects long-term persistence of tumor-specific donor T-cells. The Journal of Immunology 1984; 133: 3401–3407
   PubMed Web of Science ®Google Scholar
• Greenberg P. D. Therapy of murine leukemia with cyclophosphamide and immune Lyt-2+ -cells: cytolytic T-cells can mediate eradication of disseminated leukemia. The Journal of Immunology 1986; 136: 1917–1922
   PubMed Web of Science ®Google Scholar
• Greenberg P. D., Cheever M. A., Fefer A. Eradication of disseminated murine leukemia by chemioimmunotherapy with cyclophosphamide and adoptively transferred immune syngeneic Lyt1+ 2-lymphocytes. Journal of Experimental Medicine 1981; 154: 952–963
   PubMed Web of Science ®Google Scholar
• Greenberg P. D., Cheever M. A., Fefer A. H-2 restriction of adoptive immunotherapy of advanced tumor. The Journal of Immunology 1981; 126: 2100–2103
   PubMed Web of Science ®Google Scholar
• Greenberg P. D., Kern D. E., Cheever M. A. Therapy of disseminated murine leukemia with cyclophosphamide and immune Lyt-1+ 2-T-cells. Tumor eradication does not require participation of cytotoxic T-cells. Journal of Experimental Medicine 1985; 136: 1122–1135
   Google Scholar
• Greenberg P. D., Klarnet J. P., Kern D. E., Okuno K., Riddell S., Cheever M. Specific adoptive immunotherapy. Immunity to Cancer, M. Mitchell. Alan R. Liss, Inc, New York 1989; 11: 349–361
   Google Scholar
• Hiramoto R. N., Hiramoto N. S., Solvason H. B., Ghanta V. K. Regulation of natural immunity (NK activity) by conditioning. Annals of the New York Academy of Science 1987; 496: 545–552
   PubMed Web of Science ®Google Scholar
• Holinshead A., Elias E. G., Arlen M., Buda B., Mosley M., Scherrer J. Specific active immunotherapy in patients with adenocarcinoma of the colon utilizing tumor-associated antigens (TAA). A phase I clinical trial. Cancer 1985; 56: 480–489
   PubMed Web of Science ®Google Scholar
• Jessup J. M., McBride C. M., Ames F. C., Guarda L., Ota D. M., Romsdahl M. M., Martin R. G. Active specific immunotherapy of Dukes B2 and C colorectal carcinoma: comparison of two doses of the vaccine. Cancer Immunology Immunotherapy 1986; 21: 233–239
   PubMed Web of Science ®Google Scholar
• Juilllard G. J. F., Boyer P. J. J., Yamashiro C. H. A phase I study of active specific intralymphatic immunotherapy (ASILI). Cancer 1978; 41: 2215–2225
   PubMed Web of Science ®Google Scholar
• Kern D. E., Klarnet J. P., Jensen M. C., Greenberg P. D. Requirement for recognition of Class II molecules and processed tumor antigen for optimal generation of syngeneic tumor specific class I-restricted CTL. The Journal of Immunology 1986; 136: 4303–4310
   PubMed Web of Science ®Google Scholar
• Key M. E., Hoover H. C., Jr., Hanna M. G., Jr. Active specific immunotherapy as an adjuvant to the treatment of metastatic solid tumors: present and future prospects. Advances in Immunity and Cancer Therapy 1985; 1: 195–219
   PubMedGoogle Scholar
• Livingston P. O. The basis for ganglioside vaccines in melanoma. In. Human tumor antigens and specific tumor therapy. Alan R. Liss, Inc. 1989; 287–296
   Google Scholar
• Livingston P. O., Natoli E. J., Calves M. J., Stockert E., Oettgen H. F., Old L. J. Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients. Proceedings of the National Academy of Science USA 1987; 84: 2911–2915
   PubMed Web of Science ®Google Scholar
• Marsh B., Flynn L., Enneking W. Immunologic aspects of osteosarcoma and their application to therapy. Journal of Bone and Joint Surgery 1972; 54-A: 1367–1397
   Google Scholar
• McCune C. S., Schapira D. V., Henshaw E. C. Specific immunotherapy of advanced renal carcinoma: evidence for the polyclonality of metastasis. Cancer 1981; 47: 1984–1987
   PubMed Web of Science ®Google Scholar
• Morton D. L. Active immunotherapy against cancer. Present status. Seminars in Oncology 1986; 13: 180–185
   PubMed Web of Science ®Google Scholar
• North R. J. Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T-cells. Journal of Experimental Medicine 1982; 155: 1063–1074
   PubMed Web of Science ®Google Scholar
• Parmiani G., Sensi M. L., Carbone G., Colombo M., Pierotti M., Ballinari D., Hilgers J., Hilkens J. Cross-reactions between tumor cells and allogeneic normal tissues. Inhibition of a syngeneic lymphoma outgrowth in H-2 and non-H-2 alloimmune BALB/c mice. International Journal of Cancer 1982; 29: 323–332
   PubMed Web of Science ®Google Scholar
• Rosenberg S. A., Terry W. D. Passive immunotherapy of cancer in animals and man. Advances in Cancer Research 1977; 25: 323–388
   PubMedGoogle Scholar
• Salmon S. E. Adjuvant therapy of cancer III, S. E. Jones. Grune & Stratton, New York 1981
   Google Scholar
• Solvason H. B., Ghanta V. K., Hiramoto R. N. Conditioned augmentation of natural killer cell activity: independence from nociceptive effects and dependence on β-interferon. The Journal of Immunology 1988; 140: 661
   PubMed Web of Science ®Google Scholar
• Tai T., Cahan L. D., Tsuchida T., Saxton R. E., Irie R., Morton D. L. Immunogenicity of melanoma-associated gangliosides in cancer patients. International Journal of Cancer 1985; 35: 607–612
   PubMed Web of Science ®Google Scholar